On Friday, NextEra Energy Inc (NYSE:NEE)’s shares declined -0.46% to $99.24.
Hawaiian Electric Industries declared that HEI shareholders have approved the merger agreement with NextEra Energy, Inc. (NEE) declared Dec. 3, 2014.
Of the shares voted, about 90 percent were in favor of the merger. Achieving this level of shareholder support is a noteworthy accomplishment because, while publicly held companies commonly may proceed with a merger with the affirmative vote of a majority of their outstanding shares, HEI is required under Hawaii law to obtain supermajority approval from 75 percent of its outstanding shares. Hawaii is the only state with such a high approval requirement for a merger.
The merger will bring together two industry leaders in clean and renewable energy. Hawaiian Electric has put Hawaii on the leading edge of clean energy nationally, successfully integrating rooftop solar with 12 percent of its residential customers and assisting meet 21 percent of customer electricity needs from renewable energy resources. NextEra Energy has developed, built and operates one of the nation’s most modern grid networks and is the world’s largest producer of renewable energy from the wind and sun. NextEra Energy supports and will assist accelerate Hawaiian Electric’s plans to lower electric bills, triple distributed solar – counting rooftop solar – and achieve a 65 percent renewable portfolio standard (RPS) by 2030. This week Gov. David Ige signed a bill into law that set a aim of 70 percent RPS by 2040 and 100 percent RPS by 2045 for the state—aims which Hawaiian Electric and NextEra Energy have each stated they fully support.
NextEra Energy, Inc., through its auxiliaries, generates, transmits, and distributes electric energy in the United States and Canada. The company generates electricity from gas, oil, solar, coal, petroleum coke, nuclear, and wind sources. As of December 31, 2014, it served about 9 million people through about 4.7 million customer accounts in the east and lower west coasts of Florida. The company had about 44,900 megawatt of generating capacity.
At the end of Friday’s trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares decreased -1.11% to $65.69.
AstraZeneca plc (ADR) (NYSE:AZN) is on the road in support of cholesterol education. Earlier this year, the company launched the “Make Your Move Across America” campaign, an educational initiative offering free lipid screenings and cholesterol education to consumers across the country. The campaign began its journey in Philadelphia, traveled on to Atlanta and Louisville and will now continue on to over 15 community events that span across the country through October 2015. The campaign will visit various cities, counting Washington, D.C, Dallas and Houston, TX, Los Angeles, CA and many more.
High cholesterol is a risk factor for developing heart disease. 71 million American adults (34%) have high LDL-C (bad cholesterol). Of this group, only one out of three adults has their LDL-C level under control. Since high cholesterol has no signs or symptoms, adults must be diagnosed through a lipid profile blood test. Lifestyle modifications, counting a healthy diet and exercise may lower high LDL cholesterol levels. In some cases, when lifestyle changes do not lower cholesterol levels enough, a doctor may recommend a statin, such as CRESTOR® (rosuvastatin calcium). CRESTOR is prescribed together with diet in adults to lower high LDL (“bad”) cholesterol.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company’s medicines comprise Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.
Rovi Corporation (NASDAQ:ROVI), ended its Friday’s trading session with -3.05% loss, and closed at $17.33.
Rovi Corporation (ROVI) declared that Rovi prevailed in an infringement proceeding in Italy. The proceeding was initiated by Card Mania and Italvideo, two consumer electronics companies, alleging that the Italian portions of two European Rovi patents (EP 0969662 and EP 1377049) are invalid and not infringed. Rovi counterclaimed that the patents are valid and infringed.
In May 2015, the Court of Turin in Italy issued its decision that Rovi is entitled to a total combined judgment of about $1,000,000. The Court of Turin had formerly found the asserted patents valid and infringed by Card Mania and Italvideo.
Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The company offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording. It markets IPGs to service providers under i-Guide and Passport brands; and CE industry under the G-GUIDE and HTML Guide brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
